KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Total Current Liabilities (2016 - 2025)

Eli Lilly (LLY) has disclosed Total Current Liabilities for 17 consecutive years, with $35.2 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 24.15% year-over-year to $35.2 billion, compared with a TTM value of $35.2 billion through Dec 2025, up 24.15%, and an annual FY2025 reading of $35.2 billion, up 24.15% over the prior year.
  • Total Current Liabilities was $35.2 billion for Q4 2025 at Eli Lilly, down from $40.1 billion in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $40.1 billion in Q3 2025 and bottomed at $11.7 billion in Q1 2021.
  • Average Total Current Liabilities over 5 years is $22.2 billion, with a median of $18.8 billion recorded in 2023.
  • The sharpest move saw Total Current Liabilities dropped 7.11% in 2021, then surged 62.68% in 2025.
  • Year by year, Total Current Liabilities stood at $15.1 billion in 2021, then increased by 13.85% to $17.1 billion in 2022, then soared by 59.25% to $27.3 billion in 2023, then increased by 3.97% to $28.4 billion in 2024, then increased by 24.15% to $35.2 billion in 2025.
  • Business Quant data shows Total Current Liabilities for LLY at $35.2 billion in Q4 2025, $40.1 billion in Q3 2025, and $39.0 billion in Q2 2025.